Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
批准号:
7872069
负责人:
Allison Brashear
金额:
$9.5万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-15 至 2012-03-31
关键词:
ATP1A3 geneAddressAffectAlcoholsBiochemicalBiochemistryBiological ModelsBrainCell DeathCellsCellular biologyCephalicCharacteristicsClinicalDataDiagnosisDiseaseDisease susceptibilityDystoniaDystonia 12ElementsEvaluationEventFamilyFeverFunctional disorderGene MutationGenesGeneticGenotypeGlutamatesHeterozygoteHumanImpairmentIndividualInstitutionK ATPaseKnock-outKnockout MiceLarynxLearningMetabolicMetabolic stressMissense MutationModelingMotorMusMutant Strains MiceMutationNa(+)-K(+)-Exchanging ATPaseNeurobiologyNeurologicNeurologic ExaminationNeuronsOther GeneticsParkinson DiseaseParkinsonian DisordersPathologyPatientsPhenotypePhysiologicalPlayPredispositionPrimary DystoniasPropertyProteinsProtocols documentationPublishingQuality of lifeReportingResearch PersonnelRiskRoleSigns and SymptomsSingle Nucleotide PolymorphismStressSymptomsTestingVariantbaseclinical phenotypedisabling diseaseinterdisciplinary collaborationmeetingsmembermotor impairmentmouse modelmultidisciplinarymusiciannervous system disorderneurogeneticsneuropsychologicalpsychologicreuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Rapid-onset dystonia-parkinsonism (RDP) is an autosomal dominant disease with abrupt onset of
dystonia and parkinsonism over days to weeks followed by little improvement. In 2004, we reported that
RDP is caused by mutations in the ?3 subunit of the Na,K ATPase, the ATP1A3 gene. In 2007 we
published data on 10 families. In many of the 20 known RDP families permanent dystonia presents
acutely after stress, fever, or alcohol excess. The clinical presentation correlates with known properties
of the ?3 subunit. The Na,K-ATPase converts metabolic energy by restoring the Na+, K+
electrochemical gradient and as a result impacts neuronal activity; reuptake of glutamate and other
transmitters. The premise of this propoal is that RDP provides a window into the role of the ATP1A3
gene in brain dysfunction with the potential to impact the diagnosis and management of primary
dystonia. We hypothesize that similar to other genetic dystonias, carriers of the ATP1A3 mutations will
have a spectrum of neurologic and psychologic symptoms and that ATP1A3 plays a role in more
common dystonias. A multidisciplinary team of investigators with expertise in dystonia (Drs. Brashear
and Ozelius) and biochemistry and cell biology of Na,K-ATPase (Dr. Sweadner) has been assembled
to answer three essential questions in RDP: (1) what is the full phenotypic spectrum of ATP1A3
mutations, including motor and non-motor, (2) what is the mutational spectrum in RDP and what role
does the ATP1A3 gene have as a susceptibility factor in dystonias with characteristics similar to RDP,
and (3) what occurs at the cellular level in stressed neurons using our heterozygote ATP1A3 knockout
mouse as a model system? To answers these questions we will i] clearly define the full clinical
phenotype of RDP in the families using detailed neurologic, psychiatric and learning assessments; ii]
determine if ATP1A3 mutations are involved in the more common dystonias that share some of the
RDP characteristics (laryngeal, oromandibular, muscian's dystonia), and iii] determine the effect of
physiologic stress on the neurons in our existing heterozygote mouse. The proposed interdisciplinary
collaboration across institutions, of world experts of clinical, genetic, biochemical and neurobiological
study of dystonia and Na,K-ATPase, will deepen both our clinical and basic understanding of this
disabling disease. The results will provide a model for understanding the impact of Na,K-ATPase in
neurogenetic disorders. Narrative
Rapid-Onset Dystonia-Parkinsonism (RDP) has elements of both dystonia and Parkinson's, two neurologic
diseases with motor and neuropsychological symptoms that hinder the quality of life of millions. RDP results
from mutations in the ?3 subunit of Na K-ATPase (ATP1A3) and provides a window into the affect the ATP1A3
mutations in the brain. By defining the role of the ATP1A3 gene mutations in humans and our mouse model,
we will impact the study of other neurological diseases, including those with dystonic,
neuropsychological, and psychiatric symptoms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL, GENETIC, AND CELLULAR CONSEQUENCES OF MUTATIONS IN NA,K-ATPASE ATP1A3
-
批准号:10560390
-
项目类别:
-
资助金额:$63.19万
-
财政年份:2019
-
负责人:Allison Brashear
-
依托单位:
CLINICAL, GENETIC, AND CELLULAR CONSEQUENCES OF MUTATIONS IN NA,K-ATPASE ATP1A3
-
批准号:10031977
-
项目类别:
-
资助金额:$53.68万
-
财政年份:2019
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:7596241
-
项目类别:
-
资助金额:$63.64万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:8055282
-
项目类别:
-
资助金额:$61.9万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:8041929
-
项目类别:
-
资助金额:$3.55万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:7901388
-
项目类别:
-
资助金额:$62.04万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
CLINICAL, GENETIC, AND CELLULAR CONSEQUENCES OF MUTATIONS IN NA,K-ATPASE ATP1A3
-
批准号:10297670
-
项目类别:
-
资助金额:$71.71万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:7464591
-
项目类别:
-
资助金额:$66.16万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:8886797
-
项目类别:
-
资助金额:$67.73万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:9247875
-
项目类别:
-
资助金额:$57.96万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:9033953
-
项目类别:
-
资助金额:$59.37万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:8838340
-
项目类别:
-
资助金额:$0.14万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
-
批准号:9477121
-
项目类别:
-
资助金额:$50.69万
-
财政年份:2008
-
负责人:Allison Brashear
-
依托单位:
海外基金